Skip to main content
. Author manuscript; available in PMC: 2016 Oct 1.
Published in final edited form as: Peptides. 2015 May 11;72:128–144. doi: 10.1016/j.peptides.2015.04.026

Table 3.

BnR function in disease and/or as possible therapeutic target.

1. Tumor imaging [GRPR>NMBR, overexpressing tumors] (prostate, lung, colon, breast, pancreatic, had neck squamous cell, neuroblastomas, glioblastomas) [78,114,128,137,191,287,308,358,391]
2. BnR Targeted treatment of tumors overexpressing BnRs with cytotoxic BnR agonists/antagonists(GRPR>NMBR)
[78,114,128,137,191,287,308,358,391][Radiolabeled or other agonists or antagonists coupled to other cytotoxic agent]
3. BnR antagonists as antitumor agents [95,120–122,137,138,203]
4. Obesity, satiety disorders (GRPR>NMBR, BRS-3)[50,161,192,193,215,249,386]
5. Treatment of pruritic disorders (GRPR>NMBR)[8,95,106,158,328,333,346,377]
5. Target for psychiatric/neurological disorders [129,291–294]
6. Target for inflammatory disorders [264,266,389]